Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studies evaluating zorevunersen in patients with Dravet syndrome, a rare, severe form of epilepsy that begins in infancy.
The companies said treatment with zorevunersen, administered in addition to standard anti-seizure medications, produced sustained reductions in seizure frequency, increased seizure-free days, and improvements in cognition, behavior and overall quality of life.
The findings were presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.